Weiss Ratings Reiterates "Sell (E+)" Rating for Drugs Made In America Acquisition (NASDAQ:DMAA)

Key Points

• Weiss Ratings has reiterated a "sell (E+)" rating for Drugs Made In America Acquisition (NASDAQ:DMAA) in a recent research report.
• The stock price of DMAA remained flat at $10.30 during Wednesday's trading, with a notable 52-week range between $9.95 and $10.34.
• Several hedge funds, including Shaolin Capital Management and Boothbay Fund Management, have recently acquired new stakes in DMAA, indicating shifting institutional interest in the company.

Drugs Made In America Acquisition (NASDAQ:DMAA - Get Free Report)'s stock had its "sell (e+)" rating reissued by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Drugs Made In America Acquisition Price Performance

NASDAQ DMAA remained flat at $10.30 during trading hours on Wednesday. 308,387 shares of the company's stock were exchanged, compared to its average volume of 53,557. The stock has a fifty day moving average of $10.27. Drugs Made In America Acquisition has a 52 week low of $9.95 and a 52 week high of $10.34.

Institutional Trading of Drugs Made In America Acquisition

Hedge funds have recently made changes to their positions in the business. Shaolin Capital Management LLC acquired a new stake in shares of Drugs Made In America Acquisition during the second quarter worth about $1,020,000. Clear Street LLC acquired a new stake in shares of Drugs Made In America Acquisition during the second quarter worth about $1,149,000. Radcliffe Capital Management L.P. acquired a new stake in shares of Drugs Made In America Acquisition during the second quarter worth about $1,293,000. Mizuho Securities USA LLC acquired a new stake in shares of Drugs Made In America Acquisition during the first quarter worth about $5,402,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Drugs Made In America Acquisition during the second quarter worth about $5,814,000.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.